Posts Tagged ‘fda

September 25, 2023
Our Take: CommonSpirit launches PHSO to ‘help providers succeed in value-based care’
Read More
September 18, 2023
Our Take: J&J to rename Janssen Pharmaceuticals as part of its branding update
Read More
September 11, 2023
Our Take: Froedtert Health and ThedaCare move closer to combining, two other mergers are completed
Read More
August 28, 2023
Our Take: CVS launches new biosimilar subsidiary Cordavis
Read More
August 21, 2023
Our Take: Optum-Amedisys deal delayed after DOJ requests more information
Read More
August 14, 2023
Our Take: Novo Nordisk eyes potential cardiovascular indication for semaglutide, adds CB1 blocker to weight-loss pipeline
Read More
August 07, 2023
Our Take: CVS Health to lay off 5,000 employees as part of restructuring plan, lowers future earnings outlook
Read More
July 31, 2023
Our Take: Sanford ends proposal to merge with Fairview based on lack of support by ‘certain stakeholders’
Read More
July 24, 2023
Our Take: FEATURE: Tracking Teladoc’s ascent to, and continued presence at, the top of the telehealth industry
Read More
July 17, 2023
Our Take: Home health industry group sues federal government over rate cuts
Read More
July 10, 2023
Our Take: Amedisys chooses Optum over Option Care Health in cash deal worth more than $3 billion
Read More
June 26, 2023
Our Take: Embracing the use of ChatGPT with enthusiasm and caution, preferably in equal measure
Read More
June 19, 2023
Our Take: CMS releases list of 43 Part B drugs flagged for quarterly rebates in IRA program
Read More
June 12, 2023
Our Take: Optum makes an unsolicited $3.3 billion bid for Amedisys, potentially starting a bidding war with Option Care Health
Read More

Sign up for Our Take
the weekly strategic brief for Health Care Executives

Contact Darwin Research Group and we will get right back to you.

Reach out to us

Gainey Corporate Center
8777 N Gainey Center Dr, Ste 205
Scottsdale, AZ 85258
(480) 923-0802

Posts Tagged ‘fda

Our Take: CommonSpirit launches PHSO to ‘help providers succeed in value-based care’

Our Take: J&J to rename Janssen Pharmaceuticals as part of its branding update

Our Take: Froedtert Health and ThedaCare move closer to combining, two other mergers are completed

Our Take: CVS launches new biosimilar subsidiary Cordavis

Our Take: Optum-Amedisys deal delayed after DOJ requests more information

Our Take: Novo Nordisk eyes potential cardiovascular indication for semaglutide, adds CB1 blocker to weight-loss pipeline

Our Take: CVS Health to lay off 5,000 employees as part of restructuring plan, lowers future earnings outlook

Our Take: Sanford ends proposal to merge with Fairview based on lack of support by ‘certain stakeholders’

Our Take: FEATURE: Tracking Teladoc’s ascent to, and continued presence at, the top of the telehealth industry

Our Take: Home health industry group sues federal government over rate cuts

Our Take: Amedisys chooses Optum over Option Care Health in cash deal worth more than $3 billion

Our Take: Embracing the use of ChatGPT with enthusiasm and caution, preferably in equal measure

Our Take: CMS releases list of 43 Part B drugs flagged for quarterly rebates in IRA program

Our Take: Optum makes an unsolicited $3.3 billion bid for Amedisys, potentially starting a bidding war with Option Care Health

Sign up for Our Take
the weekly strategic brief for Health Care Executives

share

Contact Darwin Research Group and we will get right back to you.

Reach out to us

Sign up for Our Take
the weekly strategic brief for Health Care Executives

Stay Connected

Posts Tagged ‘fda

Sign up for Our Takethe weekly strategic brief for Health Care Executives

share

Contact Darwin Research Group and we will get right back to you.

Reach out to us

Sign up for Our Takethe weekly strategic brief for Health Care Executives

Stay Connected

Sign up for Our Take
the weekly strategic brief for Health Care Executives

Sign up for Our Take
the weekly strategic brief for Health Care Executives